Tech Company Financing Transactions
Kernal Biologics Funding Round
Kernal Biologics, based in Cambridge, secured $48 million in investment from Advanced Research Projects Agency for Health (ARPA-H).
Transaction Overview
Company Name
Announced On
10/7/2025
Transaction Type
Venture Equity
Amount
$48,000,000
Round
Undisclosed
Proceeds Purpose
The funds will be used to support the clinical development of Kernal Bio's in vivo mRNA-encoded CAR T-cell program, KR-402, which targets multiple sclerosis and B-cell malignancies, including acute lymphoblastic leukemia, large B-cell lymphoma and chronic lymphocytic leukemia.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
700 Main St.
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
At Kernal Bio, we aim to harness the power of our mRNA technology to provide cancer patients with treatments that give them the best chance of beating their disease -- while eliminating as many common side effects as possible. Our unique inside-out approach attacks diseases like cancer at the cellular level.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Yusuf Erkul
Co-Founder
Cafer Ozdemir
President
Burak Yilmaz
VP - Bus. Development
Maria Grunwald
Browse more venture capital transactions:
Prev: 10/7/2025: Seegrid venture capital transaction
Next: 10/7/2025: Cellectar venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs